Toralgen is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics using our unique poly-bile nanoparticle platform. This platform provides for oral delivery of many products with good bioavailability. Our nanoparticles enable localized delivery of drug agents and the potential to improve the efficacy and safety of a wide range of therapies. Toraglen currently has two preclinical candidates in preclinical testing for oral delivery of diabetes agents. Toalgen collaborates with leading pharmaceutical companies to apply our targeted delivery technology across a wide range of therapeutic areas, molecule types and routes of administration.